The active ingredient in both drugs is semaglutide, a Experts describe the development of oral GLP-1 medication as a pivotal improvement in the accessibility and adherence to obesity drugs
doi: 10.1016/j.ejphar.2008.03.025 172 GenglerSMcCleanPLMcCurtinRGaultVAHolscherC
A 2021 study even found that tooth loss, dry mouth, and having three or more oral problems as an older person are all tied to higher all-cause mortality
With an estimated $130 billion market by 2030, I believe that the market is overreacting to the current short-term issues
By slowing down the digestive process, reducing appetite, and regulating blood sugar levels, these medications offer a promising avenue for effective and holistic weight loss
Key developments to watch: Federal Level: State Level: The GLP-1 market continues evolving: Expect to see: Not all telehealth is created equal